Add to a list

Inactive Instrument

Northwest Biotherapeutics, Inc Stock Nasdaq

US66737P6007

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Northwest Biotherapeutics, Inc

Market Cap	272M 236M 220M 202M 382M 25.85B 386M 2.59B 1.01B 12.92B 1.02B 998M 42.82B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	368M 319M 298M 274M 517M 34.99B 523M 3.51B 1.37B 17.49B 1.38B 1.35B 57.96B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.2x
Free-Float	90.11%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc

Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
Apr. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Nov. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
25-08-18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
25-08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
Jul. 02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
May. 15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
Apr. 30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
Apr. 21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Maximize my profits

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC	+3.38%	+19.13%	-	-	269M
WUXI APPTEC CO., LTD.	+10.00%	+14.90%	+53.89%	+87.07%	56.7B
ARGENX SE	+0.80%	-5.70%	+23.89%	+62.65%	51.97B
BIONTECH SE	-0.98%	-1.19%	-16.98%	-14.21%	23.33B
INSMED INCORPORATED	+0.30%	-5.17%	-11.23%	+349.07%	21.34B
GENMAB A/S	+1.73%	-1.57%	+32.81%	-25.80%	17.44B
PHARMAESSENTIA CORPORATION	+4.29%	+8.97%	+200.03%	+341.85%	14.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.49%	-0.76%	+14.04%	+615.65%	14.53B
EXELIXIS, INC.	+1.71%	-0.90%	+52.13%	+176.27%	13.84B
ARROWHEAD PHARMACEUTICALS, INC.	+4.16%	+4.44%	+444.12%	+183.06%	12.12B
Average	+2.79%	+0.59%	+88.08%	+197.29%	25.12B
Weighted average by Cap.	+3.52%	+1.31%	+59.70%	+148.27%

	2026 *	2027 *
Net sales	-	38.93M 33.81M 31.52M 28.96M 54.76M 3.7B 55.36M 372M 145M 1.85B 146M 143M 6.13B
Net income	-	-
Net Debt	96.08M 83.43M 77.78M 71.46M 135M 9.14B 137M 917M 358M 4.57B 361M 353M 15.14B	125M 108M 101M 92.92M 176M 11.88B 178M 1.19B 466M 5.94B 469M 459M 19.68B

Northwest Biotherapeutics, Inc Stock Nasdaq

Stocks

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile